VJHemOnc is committed to improving our service to you

ASCO 2017 | Ponatinib and its role in treating ALL

VJHemOnc is committed to improving our service to you

Susan O’Brien

Susan O’Brien, MD from the University of California, Irvine, CA discusses the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. She explains the need to carefully adjust doses of ponatinib in treating patients due to the drug’s association with vascular events, as evaluated in a Phase II trial (NCT00671658). Overall, she explains that both trials had positive results and the future for treating ALL seems to be promising.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter